Tesla’s earnings revealed a dramatic pivot. The company is ending Model S/X production to focus on Optimus robots and AI, backed by a plan to more than double capital expenditures to over $20 billion in 2026. Wall Street analysts are deeply skeptical, warning of huge cash burn and increased risk for
Microsoft posted huge Q2 FY26 earnings with $81.3 billion in revenue, but the story is its skyrocketing AI spending. Capital expenditures hit $37.5 billion for the quarter, a 66% year-over-year jump, leaving analysts demanding to see the return on investment.
Leaked pricing for the Samsung Galaxy S26 series shows a mixed bag. The Galaxy S26 Ultra could be cheaper than its predecessor, while the base S26 model gets a price hike due to more storage.
A family-run sauna company with 45 years of history realized its internal systems were holding it back. By implementing new manufacturing software, they gained a top-down view of the business and fixed critical costing issues.
Apple’s new Creator Studio subscription bundles apps like Final Cut Pro and Logic Pro for $13 a month. But the launch is messy, with iPad users seeing a price increase and a confusing split between old and new app versions.
The UK’s competition watchdog wants to force Google to let websites opt out of having their content used in AI Overviews. This comes as publishers report significant traffic drops since the feature’s launch.
The recent US takeover of TikTok by Oracle and investors has sparked a user exodus. Many are heading to a new platform called UpScrolled, which promises free expression and no shadowbanning, but its servers are already buckling under the new traffic.
AI leaders are betting on artificial general intelligence arriving by 2030. But the pursuit of human-like machines distracts from the real, measurable value of autonomy found in predictive AI.
WIRED took the $1,999 Hypershell X Ultra and $1,899 Dnsys X1 Carbon Pro to an athletic track for a series of performance tests. The race highlighted how these emerging devices work, but also how their benefits depend entirely on the individual user. The consumer exoskeleton market is predicted to gr
While the industry dreams of AI-discovered blockbuster drugs, the real payoff is happening behind the scenes. Companies are using AI to streamline clinical trials and regulatory paperwork, saving time and millions of dollars.
